choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Tarceva

Tarceva Newsletter
  • Navigating the Treatment Landscape in Non–Clear Cell Renal Cell Carcinoma 23 Jun 2025 14:42 GMT

    … features, biologies, and treatment responses. nccRCC histologies include … excluded from RCC clinical trials, which mainly enrolled … led investigator-initiated randomized trial, patients with untreated … the EGFR inhibitor erlotinib (Tarceva) included a cohort of …

  • Supportive Care Reduces AEs With MARIPOSA Regimen in EGFR+ NSCLC 16 Sep 2025 01:00 GMT

    … 4 months of using treatment with an anticoagulant. … toxicities? The COCOON trial [NCT06120140] randomly assigned … you see with erlotinib [Tarceva] or afatinib [Gilotrif], … BioMed Valley Discoveries, Blueprint Medicines, Calithera Biosciences, Genentech…

  • Phase 1/2 Trial Investigating ATR-04 for EGFRi-Related Rashes in Lung Cancer 28 May 2025 22:23 GMT

    … 1/2 clinical trial of ATR04-484, we … the FDA for ATR04-484 in the treatment of … rash associated with EGFR inhibitors. Dr. Mary Spellman, chief medical … — including drugs like Erbitux (cetuximab), Vectibix (panitumumab), Tarceva (erlotinib) …

  • OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025 31 May 2025 02:11 GMT

    … This is the first FDA-approved treatment for LGSOC, addressing a … of trials examining avutometinib plus defactinib and excitement antibody-drug … was paired with erlotinib (Tarceva), it led to a … letter to Incyte Corporation stating that it could not …

  • A Pharmacist’s Guide to Lung Cancer and Its Key Treatments 23 Apr 2025 17:13 GMT

    … Boehringer Ingelheim) and erlotinib (Tarceva; Genentech) target EGFR mutations, … the LUX-Lung trials and erlotinib benefiting … in the CheckMate 227 trial.10 Together, these … treatments advance, targeted therapies are shifting care toward personalized medicine …

  • The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives 13 Mar 2025 15:57 GMT

    … Drug Trial Record Table Table 2 Clinical Trials of Drugs … That Sensitize Osteosarcoma Radiotherapy in the Treatment … Panpan Huang), Gannan Medical University start-up … et al. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist …

  • Advancement of First-Line Treatments on EGFR-Mutated NSCLC 18 Jan 2025 00:27 GMT

    … Hospitals Cleveland Medical Center; Giselle Dutcher, MD,medical oncologist at … ] is an important subcategory drug. I have had a … line treatment based on the phase 3 MARIPOSA-2 trial [ … gefitinib [Iressa] or erlotinib [Tarceva]. Gefitinib [was used] mainly …

  • NSCLC Experts Ponder Best First-Line Treatment Options 18 Jan 2025 00:27 GMT

    … out of recent clinical trials, particularly involving a combination … trial criteria for patients for whom they recommend the treatment … at Trinity Health IHA Medical Group; and Tarik Hadid … [added chemotherapy] to erlotinib [Tarceva] a lot back in the …

  • University of Chicago Thought Process on First-line Treatment in EGFR NSCLC 18 Jan 2025 00:27 GMT

    … ) trials.1-3 The panelists focused on how each treatment regimen … MD, associate professor of medicine. Additional panelists included James … gefitinib [Iressa] or erlotinib [Tarceva]. The median progression-free … trial was to look at arm A vs arm B. The FDA …

  • Bevacizumab plus erlotinib is highly active in HLRCC-associated papillary renal cell carcinoma 05 Sep 2025 20:44 GMT

    … (Avastin) plus erlotinib (Tarceva) elicited encouraging anti-tumor … trial (NCT01130519)published in the New England Journal of Medicine … multivariable analysis, previous treatment was shown to be … . The most common treatment-related adverse events (TRAEs …

Satisfied with the content?

Continue to create your account.